Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) shares declined 13.38 percent to close at $4.79 a share Wednesday. The stock traded between $4.38 and $5.54 on volume of 16.57 million shares traded. Analysts at Gravity Research have recently initiated coverage on the company with a "strong sell" rating. Shares of Avanir Pharmaceuticals have gained approximately 83.0 percent year-to-date.
Find out more about Avanir Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/AVNR
Sagent Pharmaceuticals Inc. (NASDAQ: SGNT) shares declined 0.37 percent to close at $21.62 a share Wednesday. The stock traded between $21.33 and $22.20 on volume of 2.95 million shares traded. Analysts at RBC Capital have recently downgraded the company’s rating to "outperform" from "sector perform". Shares of Sagent Pharmaceuticals have gained approximately 34.0 percent year-to-date.
Find out more about Sagent Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/SGNT
Sophiris Bio Inc. (NASDAQ: SPHS) shares increased 5.35 percent to close at $4.92 a share Wednesday. The stock traded between $4.70 and $5.10 on volume of 356,119 shares traded. Analysts at Lazard Capital have recently initiated coverage on the company with a "buy" rating and a price target of $10.00.
Find out more about Sophiris Bio including full access to the free equity report at:
www.RDInvesting.com/SPHS
Westlake Chemical Corporation (NYSE: WLK) shares declined 3.33 percent to close at $103.26 a share Wednesday. The stock traded between $101.14 and $105.32 on volume of 1.13 million shares traded. Analysts at JPMorgan have recently downgraded the company’s rating to "neutral" from "overweight". Shares of Westlake Chemical have gained approximately 30.0 percent year-to-date.
Find out more about Westlake Chemical including full access to the free equity report at:
www.RDInvesting.com/WLK
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com